12 Health Care Stocks Moving In Thursday's After-Market Session
Portfolio Pulse from Benzinga Insights
After-market trading on Thursday saw significant movements in several health care stocks. Aclarion, Nemaura Medical, Blue Water Biotech, Renalytix, Ontrak, and Cocrystal Pharma were among the gainers, with Aclarion leading with a 33.1% increase. The rise in these stocks followed recent earnings reports. Conversely, Kronos Bio, Biora Therapeutics, Mira Pharmaceuticals, SINTX Techs, Vicarious Surgical, and Mainz Biomed experienced declines, with Kronos Bio dropping by 14.7%. These movements also appeared to be influenced by their respective earnings reports.
November 16, 2023 | 9:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biora Therapeutics' stock decreased by 10.08% to $1.16, possibly due to its Q3 earnings report from 3 days ago.
The decline in Biora Therapeutics' stock may be a result of investor dissatisfaction with its Q3 earnings, suggesting a negative short-term impact.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Kronos Bio's shares fell by 14.7% to $0.9, following its Q3 earnings report from 3 days ago.
The significant drop in Kronos Bio's stock price suggests a negative investor response to its Q3 earnings, pointing to a short-term bearish trend.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Mira Pharmaceuticals' shares declined by 7.95% to $3.13, with no specific news to explain the drop.
The stock's decline could be due to market sentiment or a delayed reaction to past news, but without direct information, the impact is uncertain.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Mainz Biomed's stock fell 6.09% to $1.08, with its Q3 earnings report released today possibly influencing the drop.
The decline in Mainz Biomed's stock price coinciding with its Q3 earnings release suggests a direct and negative short-term impact.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Vicarious Surgical's stock dropped by 7.4% to $0.25, potentially in response to its Q3 earnings report from 3 days ago.
The stock's decline is likely a reaction to its Q3 earnings, indicating a negative short-term impact on investor sentiment.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
SINTX Techs' shares fell 7.85% to $0.39, following its Q3 earnings report from 2 days ago.
The decrease in SINTX Techs' stock price post-earnings indicates a negative market reaction, suggesting a bearish short-term impact.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Aclarion's stock surged by 33.1% to $0.45 in after-market trading, following its Q3 earnings report released 2 days ago.
The significant rise in Aclarion's stock price is likely due to a positive reception of its Q3 earnings report, suggesting short-term bullish sentiment.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Blue Water Biotech's shares rose 12.1% to $0.34, with no immediate news explaining the increase.
The stock's increase may be attributed to market speculation or investor reactions to past events, but the lack of direct news makes the impact less clear.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Cocrystal Pharma's stock increased by 8.28% to $1.7, possibly due to its Q3 earnings report from 3 days ago.
The stock's rise is likely influenced by its recent Q3 earnings, indicating a favorable short-term impact.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Nemaura Medical's stock increased by 19.12% to $0.3, though no specific news was mentioned to justify the rise.
The stock's rise could be due to market dynamics or delayed reactions to recent company developments, but without specific news, the impact analysis is less certain.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Ontrak's shares increased by 8.31% to $0.65 following its Q3 earnings report released 2 days ago.
The rise in Ontrak's stock price post-earnings suggests investor confidence and a positive short-term impact.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Renalytix's stock moved up by 11.66% to $0.67, potentially in response to its Q1 earnings report from 2 days ago.
The increase in Renalytix's stock price suggests a positive investor response to its Q1 earnings, indicating a short-term positive outlook.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100